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Abstract
Background: The long term adverse effects of Severe Acute Respiratory Syndrome (SARS), a viral disease, are
poorly understood.
Methods: Sleep physiology, somatic and mood symptoms of 22 Toronto subjects, 21 of whom were healthcare
workers, (19 females, 3 males, mean age 46.29 yrs.+/- 11.02) who remained unable to return to their former
occupation (mean 19.8 months, range: 13 to 36 months following SARS) were compared to 7 healthy female
subjects. Because of their clinical similarities to patients with fibromyalgia syndrome (FMS) these post-SARS subjects
were similarly compared to 21 drug free female patients, (mean age 42.4 +/- 11.8 yrs.) who fulfilled criteria for
fibromyalgia.
Results: Chronic post-SARS is characterized by persistent fatigue, diffuse myalgia, weakness, depression, and
nonrestorative sleep with associated REM-related apneas/hypopneas, an elevated sleep EEG cyclical alternating
pattern, and alpha EEG sleep anomaly. Post- SARS patients had symptoms of pre and post-sleep fatigue and post
sleep sleepiness that were similar to the symptoms of patients with FMS, and similar to symptoms of patients with
chronic fatigue syndrome. Both post-SARS and FMS groups had sleep instability as indicated by the high sleep EEG
cyclical alternating pattern rate. The post-SARS group had a lower rating of the alpha EEG sleep anomaly as
compared to the FMS patients. The post-SARS group also reported less pre-sleep and post-sleep musculoskeletal
pain symptoms.
Conclusions: The clinical and sleep features of chronic post-SARS form a syndrome of chronic fatigue, pain,
weakness, depression and sleep disturbance, which overlaps with the clinical and sleep features of FMS and
chronic fatigue syndrome.
Background
In light of public health concerns about the adverse effects
of the recent H1N1 pandemic viral infection, it is noted
that the long-term effects on survivors of those who sur-
vive severe illness are unknown. In this paper we report
the results of our study of the long term adverse effects of
Severe Acute Respiratory Syndrome (SARS) that emerged
from South East Asia in early 2003 as the first contempor-
ary novel severe acute infectious global health problem. In
North America, Toronto experienced the bulk of cases
that largely affected health care workers [1]. The Ontario
health authorities alerted health care personnel on March
14, 2003 about 4 family members with atypical pneumonia
that resulted in two deaths. A province-wide emergency
was declared on March 26
th, 2003 when it became evident
that these cases were the epidemiological link to SARS.
The government and health care providers took steps to
contain the spread of SARS by enacting infection control
procedures, screening and isolating those people who were
exposed, and admitting affected personnel, many of whom
were health care workers, to special hospital SARS units.
The public health precautions proved effective enough
that by June 12, 2003 there were no more new cases. Dur-
ing those 3 months 273 people were identified as being
confirmed SARS [2] cases. 44 [3] died. Because identifica-
tion of victims and containment were the orders of the
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acute phase of the illness. They were identified as having
new onset of fever, documented elevated temperature, and
were likely to have nonproductive cough, myalgia, and
dyspnea. Such individuals may have been exposed to
patients who had traveled to a location known to harbour
such cases, i.e., South China, South East Asia, or may have
acquired these symptoms as the result of direct contact or
exposure [1,4]. Subsequently a novel coronavirus was
identified as the cause of the acute outbreak [5-7].
Although the epidemic in Toronto was considered con-
trolled because no new cases appeared after June 2003
with no one remaining in quarantine [1,8] one year later
when life in the hospitals and city had returned to normal,
a cohort of post-SARS patients remained disabled and
unable to return to their work. They complained of per-
sisting debilitating physical symptoms including variable
musculoskeletal pain, profound weakness, easy fatigability,
shortness of breath that accompanied psychological dis-
tress and major sleep problems. Because of the possibility
of persistence of sleep-related respiratory dysfunction and
arousal disturbances in the sleep EEG that could affect
daytime fatigue and mood disturbances in the patients
with the greatest clinical sleep disturbances, we examined
their sleep physiology and coincident somatic and psycho-
logical symptoms. This is the first report of the long-term
adverse effects of SARS on sleep and somatic symptoms.
Methods
The University Health Network human research ethics
board approved the retrospective study of clinically
necessary sleep studies, and signed informed consent
forms were obtained from all patients. 19 females (mean
age 46.29 +/- 11.02y., BMI = 28.26 +/- 6.88) and 3 males,
(all except one being health care workers) were assessed
about 19.8 months after onset of the acute SARS illness
(range: 13 to 36 months) with hospitalization and/or
quarantine for SARS. They were part of a cohort of
50 post-SARS patients who had come under the care of
the Ontario Workers’ Safety and Insurance Board
(WSIB) because of persistent impaired health that inter-
fered with their hospital work capabilities. They had been
sent by WSIB for a complex, intense, interdisciplinary
clinical program of physical and psychological restorative
rehabilitation. This post-SARS group was compared to a
small group of younger healthy 8 females (mean age
30 +/- 6.7 y., p = 0.0002), but with a similar BMI
(24.8 +/- 6.1, p =.242) by employing standard self-ratings
of physical symptoms [the Wahler Physical Symptom
Inventory (WPSI)] [9], of depression [Beck Depression
Inventory (BDI)] [10,11], of self rated symptoms of post
traumatic stress disorder (PTSD) because of their expo-
sure to the threat of death as the result of their exposure
to the SARS virus[PTSD check list civilian version {PCL-
C}] [12], and of sleep symptoms [the Sleep Assessment
Questionnaire
c (SAQ
c)] [13]. The SAQ is a 17-item ques-
tionnaire that has been found to be useful for identifying
sleep disorders related to chronic fatigue. One overnight
polysomnography was employed in order to objectively
evaluate sleep physiology. The procedures included elec-
troencephalogram (EEG C3, C4) electro-oculogram, sub-
mental and bilateral anterior tibialis electromyogram,
single anterior lead electrocardiogram, measures of
respiration comprising measures of airflow with oral-
nasal thermistors and respiratory impedance plethysomo-
graphy, and pulse oximetry. An experienced registered
polysomnographic technologist completed blind ratings
of sleep physiological indices [14] and standardized rat-
i n g s( 1t o5 )o ft h ep r e s e n c eo fam e a s u r eo fa r o u s a li n
the non rapid eye movement sleep EEG (NonREM sleep),
known as the alpha frequency anomaly [15] where 1 was
the percentage of alpha EEG in Non REM sleep (7.5 Hz
to 12Hz) less than 20% and where 5 was more than 80%
of alpha EEG in Non REM sleep. In order to evaluate
daytime lethargy the overnight sleep study was followed
by the multiple sleep latency test (MSLT) comprising of
at least four 20 minute nap opportunities at 2 hour inter-
val beginning 2 hours after morning awakening [16]. Self
ratings of symptoms pre-sleep and post sleep consisted
of standard measures of total regional musculoskeletal
pain severity (0-24), of fatigue (1-7) [17], and sleepiness
[18] that had been used in previous studies of patients
with fibromyalgia syndrome (FMS) and chronic fatigue
syndrome (CFS). Because clinically the post-SARS
patients described many of the features seen in patients
with FMS we also compared the self ratings of pain, fati-
gue and sleepiness symptoms and objective indices of
overnight sleep physiology to an aged matched popula-
tion of 21 drug free female patients, (mean age 42.4 +/-
11.8 yrs.) who fulfilled criteria for fibromyalgia [19]. They
had participated in a double blind placebo- controlled
drug trial, to which they had provided their ethics
approved signed consent. Only the initial overnight pre-
treatment sleep study was employed for the purposes of
comparison with this post-SARS chronically ill patient
population. In addition to the standard sleep physiologi-
cal indices described above we analyzed another sleep
EEG anomaly known as a high frequency of cyclical alter-
nating pattern (CAP). The CAP rate has been found to be
a quantified measure of EEG sleep stability where fre-
quent periodic EEG arousal disturbances indicate sleep
instability or poor quality sleep. This high frequency of
CAP has been related to less efficient sleep and the sever-
ity of symptoms of patients with FMS [20,21]. Objective
ratings of CAP rate was assessed using a validated, com-
puterized automatic detection methodology (Somnolo-
gica) [22,23]. Statistical analyses were completed between
group 2 tail t-tests for behavioural self-ratings, sleep
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rent symptoms. Bonferroni corrections were performed
on the multiple t tests.
Results
In comparison to healthy subjects, post-SARS subjects
reported more physical symptoms on the WPSI (mean
10.6 +/- 5.0 vs. 0.4 +/- 0.5, p <.0001). On most days
they complained of tiredness, difficulty sleeping, myalgia
and muscular weakness. They had more mild to moder-
ate depressive symptoms (BDI mean = 13.3 +/- 8 vs.0.86
+/- 1.5, p < .0001), more sleep disturbances on the
SAQ
c (mean total score = 30.9 +/- 5 vs. 10.9 +/- 3.4,
p < .0001), more fatigue post-sleep (p <.05), and more
myalgia pre- and post-sleep (p < .01). See Table 1. For
the 21 patients that completed the PCL-C, the mean
score was 40.75 +/- 10.26. Two patients had scores of
50 or more that would be suggestive of the symptoms
seen in patients with PTSD [24].
The overnight sleep physiology in the post-SARS
group showed more arousal disturbances and the alpha
EEG sleep disorder which consists of the anomalous
appearance of the EEG alpha frequency (7.5-12 Hz) in
approximately 50% of sleep. There was more stage 2
NonREM sleep and a delay in onset to REM sleep, but
no other significant differences in measures of sleep
EEG. See Table 1.
In measures of sleep-related respiratory disturbances,
5 post-SARS subjects who snored had variable daytime
sleepiness on the MSLT (defined as rapid onset to sleep
in less than 8 min on at least one of the 4 or 5 nap
opportunities, range from 3-8 min). Two of these Post-
SARS subjects (ages 63 yrs., BMI = 28, and 49 yrs, BMI
= 32) who were being treated for hypertension had
moderate and mild sleep hypopnea/apnea disorder (with
a respiratory distress index (RDI) = 18.8 and 8.4 respec-
tively) and arterial oxygen desaturation (minimum of
81.2% and 83% respectively). The only other person (age
57 yrs, BMI 25.5) being treated for hypertension had
very mild elevation of RDI (7.5) but no snoring, no sig-
nificant sleep-related arterial oxygen desaturations or
daytime sleepiness. The others had no specific distur-
bances in sleep-related respiration. The limited number
of healthy subjects and their incomplete detailed data
on REM and NonRem arterial blood oxygen saturations
did not permit proper comparison with such data from
the post-SARS group.
Although most complained of being depressed only
two were receiving antidepressants (citalopram), one of
which had sleep apnea. All patients were seen by clinical
psychologists unless they declined to do so, and psychia-
tric consultation was available to all if requested by the
patient or other team members.
I nt h ec o m p a r i s o nb e t w e e nt h ep o s t - S A R S&F M S
patients there were no clinically significant sleep related
breathing disturbances or periodic leg movements dur-
ing sleep. Both groups had a similarly elevated measure
of sleep instability as indicated by the high cyclical alter-
nating pattern rate [22,23], compared to the published
norms as reported by Parrino [25] et al. These are also
comparable to the findings of Rizzi et al in their study
of CAP in FM patients.
FMS patients, however, showed a significantly higher
rating of the alpha EEG sleep anomaly than did the post-
SARS patients. Other than there being more NonREM
stage 2 sleep and a relative delay in onset to the initial
REM sleep episode there were no other differences in
their stages of sleep EEG. In their ratings of somatic
Table 1 Sleep in SARS vs. Healthy Controls
Sleep Parameter SARS Healthy Controls Significance
Mean (SD) Mean(SD) P
Sleep onset latency ( min.) 24.13 (21.63) 29.34(31.48) n.s.
Total sleep time (min) 370.83 (83.84) 343.43(38.47) n.s.
Sleep Efficiency % 77.44 (13.56) 83.23( 12.36) n,s.
Stage 1% 9.11 (4.13) 6.60(4.61) n.s.
Stage 2% 60.22 (9.95) 49.77(6.53) p = 0.006
Stage 3% 7.83 (6.36) 4.84(2.11) n.s.
Stage 4% 6.27 (5.80) 9.70 (2.84) p = 0.051.
REM onset Latency ( min.) 136.79 (63.72) 87.23 (38.47) p = 0.004
REM % 16.57 (5.94) 17.27 (5.35) n.s.
Apnea/Apnea-Hypopneas Index (no. per hr.of sleep) 4.70 (5.53) 2.73 (2.08) n.s.
REM Apnea-Hypopnea Index (no. per hr.of REM sleep) 14.33 (15.41) N/A N/A
NREM 02 saturation (max/min) 99.13 (0.68) 92.09 (3.61) N/A N/A
REM 02 saturation (max/min) 98.69 (0.93)/92.24 (4.60) N/A 96.50 (0.71) N/A N/A
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sleep fatigue and sleepiness similar to that reported by
patients with FMS. Unlike the FMS patients they com-
plained of less pre sleep and post sleep musculoskeletal
pain symptoms (see table 2). See Table 2.
Discussion
This is the first report of the long-term adverse effects
of widespread chronic pain, fatigue, psychological dis-
tress and disturbed sleep after acute SARS that contrib-
uted to the failure to return to productive work of a
small cohort of health care professionals at least one
year after their acute illness. After their initial SARS
symptoms of severe respiratory distress, fever with evi-
dence for infiltrates in their lungs had remitted so that
they were considered to be no longer in need of special
quarantine and acute treatment measures, a constella-
tion of symptoms persisted that interfered with their
ability to function in their occupations. This was then a
potentially biased selection process of 22 patients who
were members of a group of 50 chronically ill survivors
of SARS. A larger study of 107 patients from Toronto,
with a more widely selected population [26] had shown
that, at the one year mark some continued to describe
problems with pain, reduced vitality, physical, mental,
and social functioning. Only 14 (13%) were asympto-
matic, leaving 93 patients (87%) symptomatic, where 18
( 1 7 % )h a dn o tr e t u r n e dt ow o r k ,a n d1 0( 9 % )h a d
returned to modified work. If one presumes that the
asymptomatic group was most likely to return to unmo-
dified work, then of the 79 patients returning to unmo-
dified work, only 14 were asymptomatic. This leads to
the arithmetic conclusion that 65 (82%) of their patients
who returned to unmodified work were nevertheless
continuing to work despite ongoing symptoms.
Furthermore, 5 of our 22 subjects showed variable
daytime sleepiness, which was associated with snoring
indicative of sleep disordered breathing, but not neces-
sarily overt sleep apnea. While sleep-related breathing
disturbances have been reported in some patients with
FMS/CFS [27-29] only three post-SARS subjects exhib-
ited mild to moderate sleep apnea/hypopneas. However,
they may have had this sleep disorder before SARS
because they were being treated for hypertension, a
common causal risk for untreated sleep apnea [30].
Nevertheless, these sleep-related respiratory disturbances
together with the alpha EEG sleep disorder may have
contributed to their unrefreshing sleep and daytime
symptoms.
Our single overnight study showed sleep physiological
changes in stage 2 and REM onset latency that may
have been influenced by being a feature of the potential
adverse effect on sleep of the procedures employed in
the study, known as the first night effect. The groups,
however, were compared under similar circumstances
although the SARS healthcare subjects may have been
Table 2 Sleep, Pain and Fatigue in SARS vs. FMS Subjects
Sleep Parameter SARS (n = 22) Fibromyalgia (n = 21) Significance
Mean (SD) Mean (SD)
Sleep onset latency ( min.) 24.13 (21.63) 18.37 (35.39) n.s.
Total sleep time (min) 370.83 (83.84) 338.54 (76.26) n.s.
Sleep Efficiency % 77.44 (13.56) 79.34 (15.63) n.s.
Stage 1% 9.11 (4.13) 9.76 (3.66) n.s.
Stage 2% 60.22 (9.95) 54.61(5.41) 0.031
Stage 3% 7.83 (6.36) 7.35 (3.08) n.s.
Stage 4% 6.27 (5.80) 9.53 (6.18) n.s.
REM onset Latency ( min.) 136.79 (63.72) 87.26 (35.78) 0.004
REM % 16.57 (5.94) 18.77 (4.81) n.s.
Apnea/Hypopneas Index (no. per hr.of sleep) 4.70 (5.53) 3.29 (2.37) n.s.
Periodic leg movements ( no.per hr of sleep) 2.03 (5.64) 2.38 (3.81) n.s.
Arousals per hr of sleep 14.01 (7.59) 11.31 (5.31) n.s.
CAP rate per hr of sleep 71.64 ()(14.25) 70.39 (15.64) n.s.
Alpha EEG sleep (1-5) 3.00 (0.63) 3.50(0.61) 0.014
Presleep Pain Presleep Fatigue (1-7) 6.24 (4.01) 4.57 (1.57) 10.95 (5.74) 4.30 (1.08) 0.005 n.s.
Presleep Sleepiness (1-7) 2.76 (1.14) 4.30 (1.08) 0.0001
Post Sleep Pain (0-24) 7.10 (3.81) 11.75 (6.45) 0.009
Post Sleep Fatigue (1-7) 4.30 (1.87) 4.60 (1.23) n.s.
Post Sleep Sleepiness (1-7) 3.45 (1.57) 3.90 (1.12) n.s.
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and being more depressed. The two who were receiving
antidepressant medications (citalopram) did not differ in
any of the sleep parameters from the others who were
equally depressed and not receiving such medications.
In our cohort, their disabling chronic fatigue, variable
nonspecific myalgia, depression and sleep disturbances
are similar to those experienced by patients with post-
febrile Chronic Fatigue Syndrome (CFS) [31] and Fibro-
myalgia Syndrome (FMS) [32]. Indeed, physiological
changes in their sleep EEG, i.e., the alpha EEG sleep
anomaly is a common feature in such patients who
commonly complain of unrefreshing sleep, fatigue, mus-
culoskeletal pain, impaired cognitive functioning, and
emotional distress [21,23,33-36]. In the comparison of
the post-SARS patients to the FMS subjects we noted
similar sleep EEG elevated cyclical alternating pattern
rate as previously reported by ourselves and others
[22,23]. However, in this study both the alpha EEG
sleep ratings and the pain ratings were greater in FMS
disorder than the post-SARS patients. Indeed the post-
SARS patients seem to be similar to CFS patients where
their focus is on fatigue symptoms rather than the pain.
Some contribution to the post-SARS persistent sleep,
pain, fatigue, and depressive symptoms may have
occurred as the result of the psychologically traumatic
effects of their acute infectious illness. That is, these
symptoms may have arisen as the result of their isola-
tion from family and friends, uncertain outcome and
threat of death. While as a group the post-SARS
patients did rate themselves as having psychological
distress only 2 patients described features on the PCL-C
rating scale that are attributed to those with PTSD [12].
Such distressing experiences together with their acute
SARS may have contributed to their alpha EEG arousal
disturbances in sleep, recurrent nightmares and their
inability to obtain restful sleep. Sleep difficulties have
been reported in health care workers who did not have
SARS themselves, but who did care for patients with
SARS [37]. Indeed, similar unrefreshing sleep, fatigue
and musculoskeletal pain symptoms occur in healthy
people who have been experimentally exposed to several
nights of frequent noise induced disruption of slow
wave sleep, which artificially produces the periods of the
alpha EEG sleep [38].
In addition there is the possibility that the sleep disor-
der, fatigue and behavioral symptoms may have occurred
as the result of the Coronavirus A directly; this virus is
known to invade the central nervous system and periph-
eral tissues [39,40]. Viral particles and viral genome
sequences were isolated from the cytoplasm of neurons
more commonly in the hypothalamus and the cortex
[41,42]. Although the evidence indicates that the virus
crosses the blood-brain barrier into the brain, the route
of infection in humans remains unknown [43]. In mice
that are transgenic for the SARS-CoV receptor (human
angiotensin-converting enzyme 2) the virus enters the
brain primarily via the olfactory bulb. Thereafter the
infection spreads rapidly via neurons throughout the
brain [44]. The virus may have resulted in chronic post-
inflammatory CNS pathology that adversely affects sleep,
pain sensitivity, and energy. In previous studies of
Table 3 Published Studies
re Patients Post-SARS (re Sleep)
Location Followup Time Outcomes
Toronto Acute illness (Retrospective) no discussion sleep [2]
21 day no discussion of sleep [1]
3 weeks post discharge Appears to be 100% prevalence insomnia (two cases were severe) [4]
One year complaints of sleep disturbance averaging 47% prevalence [26]
Asia “peak of outbreak” Sleep problems noted, no incidence given [50]
6 months No discussion sleep [51]
Summary 2005 No discussion sleep [52]
Summary 2006 No discussion sleep [53]
re Health Care Workers Not Ill With SARS (re Sleep)
Toronto 4 weeks No prevalence given, but “sleep may be the first casualty”[54]
~ 5 months “Stigma, fear, frustration” but no discussion sleep [55]
26 months Negative psychological effects but no discussion sleep [56]
Asia 5 weeks No discussion sleep [57]
April, May 2003 No discussion sleep [58]
3 months Sleep “poor”, improved by prevention program [37]
30 months “Mental health catastrophe” but no discussion sleep [59]
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ness [45] and symptom-attributional style and physician
behaviour [46] have been associated with such outcomes.
The literature regarding SARS has documented many
physical and psychological sequelae of the illness in
both the short and the long term. Many studies did not
note sleep disturbances, most likely on the basis that the
focus of the study was elsewhere, even when one would
expect sleep disturbances - such as when reporting inci-
dence of post traumatic stress disorder (PTSD). In the
studies where questions were asked about sleep, sleep
disturbances were noted, although prevalence numbers
are hard to find (table 3).
Conclusions
Chronic post-SARS is characterized by persistent fatigue,
diffuse myalgia, weakness, depression, and nonrestorative
sleep with associated REM-related apneas/hypopneas and
alpha EEG sleep disorder. These clinical and sleep fea-
tures of chronic post-SARS are similar to those features
which may be found in patients with chronic fatigue syn-
drome/fibromyalgia. This report of the possible contribu-
tion of the coronaviral SARS to the emergence of chronic
fatigue, unrefreshing sleep fatigue and widespread mus-
culoskeletal pain symptoms also raises the question of
the specificity the infectious retrovirus, XMRV, in blood
cells that was recently reported [47] but is now a source
of controversy as to its significance and specificity for
patients with chronic fatigue syndrome [48,49]. A longer
term, large scale study is needed to establish the contri-
bution of epidemic and pandemic viral disease to the dis-
ordered sleep, chronic fatigue and somatic symptoms of
chronic fatigue/fibromyalgia syndrome.
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